Fmr LLC trimmed its holdings in Inogen Inc (NASDAQ:INGN) by 88.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,300 shares of the medical technology company’s stock after selling 263,662 shares during the period. Fmr LLC owned 0.16% of Inogen worth $6,391,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. BlackRock Inc. lifted its stake in shares of Inogen by 7.2% in the second quarter. BlackRock Inc. now owns 2,591,083 shares of the medical technology company’s stock worth $482,796,000 after buying an additional 173,035 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of Inogen by 186.2% in the second quarter. Jennison Associates LLC now owns 119,570 shares of the medical technology company’s stock worth $22,279,000 after buying an additional 77,791 shares during the last quarter. Fred Alger Management Inc. lifted its stake in shares of Inogen by 25.5% in the second quarter. Fred Alger Management Inc. now owns 311,349 shares of the medical technology company’s stock worth $58,014,000 after buying an additional 63,308 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Inogen by 2,649.5% in the second quarter. Acadian Asset Management LLC now owns 55,155 shares of the medical technology company’s stock worth $10,277,000 after buying an additional 53,149 shares during the last quarter. Finally, State of Wisconsin Investment Board lifted its stake in shares of Inogen by 79.4% in the second quarter. State of Wisconsin Investment Board now owns 40,000 shares of the medical technology company’s stock worth $7,453,000 after buying an additional 17,700 shares during the last quarter. 96.47% of the stock is owned by institutional investors.

In related news, EVP Brenton Taylor sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $197.80, for a total transaction of $989,000.00. Following the completion of the transaction, the executive vice president now directly owns 41,576 shares in the company, valued at approximately $8,223,732.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Raymond Huggenberger sold 10,500 shares of the company’s stock in a transaction on Friday, September 14th. The shares were sold at an average price of $282.57, for a total transaction of $2,966,985.00. Following the transaction, the director now owns 8,797 shares of the company’s stock, valued at $2,485,768.29. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,234 shares of company stock valued at $21,656,659. Corporate insiders own 5.29% of the company’s stock.

A number of analysts have recently weighed in on INGN shares. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $276.00 price objective for the company in a research note on Tuesday, August 28th. BidaskClub cut shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. Stifel Nicolaus set a $258.00 price objective on shares of Inogen and gave the stock a “buy” rating in a research note on Tuesday, August 21st. Finally, Needham & Company LLC restated a “buy” rating on shares of Inogen in a research note on Wednesday, June 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Inogen has an average rating of “Buy” and a consensus target price of $247.33.

NASDAQ:INGN opened at $196.10 on Thursday. The firm has a market cap of $5.21 billion, a P/E ratio of 149.69, a P/E/G ratio of 4.83 and a beta of 1.26. Inogen Inc has a one year low of $93.10 and a one year high of $287.79.

Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, August 7th. The medical technology company reported $0.65 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.21. The firm had revenue of $97.24 million during the quarter, compared to analysts’ expectations of $81.61 million. Inogen had a net margin of 10.39% and a return on equity of 16.51%. Equities analysts predict that Inogen Inc will post 2.07 earnings per share for the current year.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading: Fundamental Analysis and Choosing Stocks

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.